Fabros, a subsidiary of Kimia Farma (Persero) Tbk, announced a net profit of 761.49 million rupiah in the first quarter of 2026, reflecting a remarkable increase of 113% compared to the same period last year. This growth resulted from a 10.17% increase in the company's sales, which reached 221.09 billion rupiah, while production costs rose by only 5.04%.
The interim general manager of Fabros, Ida Rahmi Kurniasih, stated that these results reflect the company's ability to adapt to global challenges, highlighting the importance of strategies to improve distribution channels and ensure product availability. She also confirmed that the company continues to implement strategies to enhance efficiency and reduce costs.
Sales Performance and Growth
Fabros has successfully boosted its sales of generic drugs, with sales increasing by 59% to reach 128.70 billion rupiah. This success aligns with the efforts of the Indonesian government to strengthen the healthcare sector, as Fabros is considered one of the leading pharmaceutical companies in the country.
In 2025, Fabros achieved a 109% increase in profits, indicating a continuous positive trend in the company's financial performance.
Background & Context
Fabros was established as part of the Indonesian government's efforts to enhance the healthcare sector, and it has managed to turn previous losses into profits, reflecting the success of its strategies in facing economic challenges.
Impact & Consequences
The significant profit growth achieved by Fabros demonstrates the ability of Indonesian companies to adapt to changing economic conditions, which may encourage further investments in the pharmaceutical sector and enhance Indonesia's capacity to meet its healthcare needs.
Regional Significance
This performance is crucial not only for Fabros but also for the broader Indonesian economy, as it showcases the potential for growth within the pharmaceutical industry. The success of Fabros may inspire other companies to innovate and improve their operations.
In conclusion, Fabros's remarkable achievement in the first quarter of 2026 serves as a testament to the resilience and adaptability of Indonesian businesses in the face of economic challenges, reinforcing confidence in the healthcare sector.